Table 3

Post-recurrence survivors

	Stage	Adjuvant treatment	Time to recurrence (months)	Site of recurrence	Treatment for recurrence	Post-recurrence survival (months)	Disease status
1	IA	Observation	45	Groin, pelvic and PA LN	chemotherapy	1.1	AWD
2	IA	Observation	48.6	Pelvic mass	SX, chemotherapy	125.6	PDF*
3	IC	RT	91	PA LN	RT, chemotherapy	90.5	PDF
4	IC	RT	16	Pelvic mass	SX	34.1	PDF
5	IC	Observation	24	Pelvic mass	SX+RT	5.4	NED
6	IIC	Chemotherapy +RT	21.6	Lung nodules	Clinical trial	29	AWD
7	IC	Observation	30.5	PA LN	Observation†	30	AWD
8	IC	Observation	21.8	Pelvic mass	SX	66.5	PDF
9	IA	Observation	2.1	‡Diffuse abdopelvic carcinomatosis intra-abdominal masses and cardiophrenic LN	Chemotherapy	96.8	PDF
10	II	Chemotherapy	24.6	Pelvic mass	RT	42.9	PDF
11	III	Chemotherapy	24.9	Pelvic, PA and mediastinal LN	Clinical trial	1.8	AWD
12	IA	Chemotherapy	82	PA LN	SX	5.4	AWD
13	IC	Chemotherapy	31.6	Pelvic and PA LN	Chemotherapy	29.1	AWD

NOT included in the table: two patients who were discharged to hospice and one patient who was lost to follow-up after recurrence.
*Died of stroke 10 years after recurrence, no evidence of disease.
†The patient refused treatment, the PA mass is slowly growing and monitored by imaging, with no signs of other disease sites.
‡Recurrence ascites was sent for cytology at time of recurrence, and reported as adenocarcinoma.
AWD, alive with disease; LN, lymph nodes;NED, no evidence of disease; PA, para-aortic; PDF, prolonged disease-free survival post-recurrence (no evidence of disease >30 months after recurrence); RT, radiation; SX, surgery.